OncoDNA Overview

  • Year Founded
  • 2012

Year Founded

  • Status
  • Private

  • Employees
  • 120

Employees

  • Latest Deal Type
  • Later Stage VC

  • Investors
  • 17

OncoDNA General Information

Description

Operator of a theranostic and genomic company intended to provide precision medicine to treat cancer and genetic diseases. The company provides clinical guidance for the treatment and real-time monitoring of late-stage cancer patients and also supports research and drug development in cancer and genetic diseases, helping clinicians, academic researchers, and biopharma companies to outsmart molecular complexity with the mission of delivering the promise of precision medicine.

Contact Information

Website
www.oncodna.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Rue Louis Breguet 1
  • 6041 Gosselies
  • Belgium
+32 071
Primary Industry
Biotechnology
Other Industries
Other Healthcare Technology Systems
Other Devices and Supplies
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • Rue Louis Breguet 1
  • 6041 Gosselies
  • Belgium
+32 071

OncoDNA Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

OncoDNA Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Later Stage VC 11-Jul-2024 Completed Generating Revenue
7. Later Stage VC (Series C) 05-Jul-2023 Completed Generating Revenue
6. Later Stage VC 09-Aug-2021 Completed Generating Revenue
5. Later Stage VC (Series B) 20-Apr-2020 Completed Generating Revenue
4. Later Stage VC 15-Feb-2019 Completed Generating Revenue
3. Early Stage VC (Series A) 01-Sep-2016 Completed Generating Revenue
2. Early Stage VC 15-Dec-2015 $538K $3.1M Completed Generating Revenue
1. Early Stage VC 01-Dec-2012 $2.57M $2.57M Completed Generating Revenue
To view OncoDNA’s complete valuation and funding history, request access »

OncoDNA Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Class C
Preferential Shares
Ordinary
Ordinary
Ordinary 240,715 $0.76 $0.76 1x $0.76 1.9%
Ordinary 125,000 $4.35 $4.35 1x $4.35 0.99%
To view OncoDNA’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

OncoDNA Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a theranostic and genomic company intended to provide precision medicine to treat cancer and genetic disease
Biotechnology
Gosselies, Belgium
120 As of 2026

Oxford, United Kingdom
 

South San Francisco, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

OncoDNA Competitors (13)

One of OncoDNA’s 13 competitors is Oxford Nanopore Technologies, a Formerly VC-backed company based in Oxford, United Kingdom.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Oxford Nanopore Technologies Formerly VC-backed Oxford, United Kingdom
Quantapore Venture Capital-Backed South San Francisco, CA
Abionic Venture Capital-Backed Lausanne, Switzerland
DNAe Formerly VC-backed London, United Kingdom
QuantuMDx Venture Capital-Backed Newcastle Upon Tyne, United Kingdom
You’re viewing 5 of 13 competitors. Get the full list »

OncoDNA Patents

  • 34

    Total Documents Applications and Grants

  • Total Patents Families

  • 2

    Granted

  • 18

    Pending

  • Expiring in next 12 mo

OncoDNA Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4364752-A1 Improved vaccine Inactive 07-Nov-2022
EP-4615491-A1 Improved vaccine Pending 07-Nov-2022
US-20260151468-A1 Improved vaccine Pending 07-Nov-2022
WO-2024100025-A1 Improved vaccine Inactive 07-Nov-2022
CA-3230575-A1 A rna vaccine comprising an rna pool generated from a double-stranded dna pool Pending 13-Sep-2021 A61K39/0011
To view OncoDNA’s complete patent history, request access »

OncoDNA Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

OncoDNA Investors (17)

Investor Name Investor Type Holding Investor Since Participating Rounds
SFPI Corporation Minority
Wallonie Entreprendre Growth/Expansion Minority
Société Fédérale de Participations et d'Investissement Holding Company Minority
Swisscanto Holding Asset Manager Minority
Verve Ventures Venture Capital Minority
You’re viewing 5 of 17 investors. Get the full list »

OncoDNA Acquisitions (2)

OncoDNA’s most recent deal was a Merger/Acquisition with IntegraGen for . The deal was made on 17-Nov-2020.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
IntegraGen 17-Nov-2020 Merger/Acquisition Biotechnology
BioSequence 23-Feb-2017 Merger/Acquisition Drug Discovery
To view OncoDNA’s complete acquisitions history, request access »

Ready to get started?

Request a free trial

OncoDNA Affiliates

Subsidiaries (1)

Name Industry Location Year Founded
BioSequence Valencia, Spain 2012

OncoDNA FAQs

  • When was OncoDNA founded?

    OncoDNA was founded in 2012.

  • Where is OncoDNA headquartered?

    OncoDNA is headquartered in Gosselies, Belgium.

  • What is the size of OncoDNA?

    OncoDNA has 120 total employees.

  • What industry is OncoDNA in?

    OncoDNA’s primary industry is Biotechnology.

  • Is OncoDNA a private or public company?

    OncoDNA is a Private company.

  • What is OncoDNA’s current revenue?

    The current revenue for OncoDNA is .

  • How much funding has OncoDNA raised over time?

    OncoDNA has raised $56.7M.

  • Who are OncoDNA’s investors?

    SFPI, Wallonie Entreprendre, Société Fédérale de Participations et d'Investissement, Swisscanto Holding, and Verve Ventures are 5 of 17 investors who have invested in OncoDNA.

  • Who are OncoDNA’s competitors?

    Oxford Nanopore Technologies, Quantapore, Abionic, DNAe, and QuantuMDx are some of the 13 competitors of OncoDNA.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process